Waltham biotech Tesaro Inc. announced Tuesday morning it has raised $101 million in a Series B round of venture capital led by West Coast venture firm Kleiner Perkins Caulfield & Byers.
Tesaro was founded in 2010 with a $20 million Series A from venture firm New Enterprise Associates, and a plan to acquire, license and develop cancer drug candidates.